Results 251 to 260 of about 814,690 (301)
Some of the next articles are maybe not open access.
1996
Antiandrogens are effective drugs in the treatment of advanced prostatic cancer. The main problems associated with their use are their short half-lives, leading to fluctuating serum levels, and their non-selectivity, which leads to increases in serum LH and testosterone through centrally-mediated actions.
openaire +2 more sources
Antiandrogens are effective drugs in the treatment of advanced prostatic cancer. The main problems associated with their use are their short half-lives, leading to fluctuating serum levels, and their non-selectivity, which leads to increases in serum LH and testosterone through centrally-mediated actions.
openaire +2 more sources
Preclinical toxicology studies with tobramycin
Toxicology and Applied Pharmacology, 1973Abstract Tobramycin, an aminoglycoside antibiotic, has been administered to mice, rats, cats and dogs for toxicologic evaluation. The sc LD50 values in mice and rats were 441 and 969 mg/kg, respectively. Deaths were preceded by CNS depression and occurred within 1 hr of treatment.
J S, Welles +5 more
openaire +2 more sources
Preclinical studies with Erlotinib (Tarceva)
Seminars in Oncology, 2003Erlotinib HCl (Tarceva; Genentech, Inc, South San Francisco, CA) is an orally available, highly selective, reversible inhibitor of epidermal growth factor receptor (HER1/EGFR) tyrosine kinase. Inhibition of tyrosine kinase activity prevents HER1/EGFR phosphorylation, the associated downstream signaling events, and may block tumorigenesis mediated by ...
Robert W, Akita, Mark X, Sliwkowski
openaire +2 more sources
Preclinical safety studies of cefmetazole
Journal of Antimicrobial Chemotherapy, 1989In order to assess the safety of cefmetazole, preclinical multiple-dose parenteral studies, varying from one to three months in length, were conducted in Sprague-Dawley rats and beagle dogs. Although the largest doses used were in multiples of several times the weight-adjusted doses intended for humans, cefmetazole was generally well tolerated.
J B, Moe +4 more
openaire +2 more sources
Preclinical Studies with Small Animal PET
PET Clinics, 2011Because no effective cures are available for cutaneous malignant melanoma, early diagnosis and accurate staging are of the utmost importance in increasing patient survival. Fluorodeoxyglucose positron emission tomography (PET)/computed tomography is a functional imaging technique that has contributed to ameliorating surveillance of patients with ...
NANNI, CRISTINA, FANTI, STEFANO
openaire +3 more sources
Forodesine – Preclinical Studies
Hematology Meeting Reports, 2009Chemically forodesine is [(1S)-1-(9-deazahypoxanthin-9-yl)-1,4-dideoxy-1,4-imino-D-ribitol]. The agent is also known as immucillin hypoxanthine (immucillin H) or BCX-1777. This is a potent inhibitor of the enzyme purine nucleoside phosphorylase (PNP).
openaire +1 more source
Preclinical Study Design for rAAV
2011The process of moving a novel drug such as an adeno-associated viral vector from the bench top to bedside is an arduous process requiring coordination and skill from multiple laboratories and regulatory agencies. Proceeding to a phase I safety trial in humans after most of the proof-of-concept data have been acquired may take several years. During this
Terence R, Flotte +2 more
openaire +2 more sources
Preclinical studies of dendrimer prodrugs
Expert Opinion on Drug Metabolism & Toxicology, 2015Dendrimers are synthetic macromolecules with well-defined structures bearing a wide variety of functional groups on their periphery. These groups can be used to conjugate bioactive molecules such as drugs, ligands and imaging agents. Dendrimer prodrugs can be used to improve the water solubility and pharmacokinetic properties of the corresponding free ...
openaire +2 more sources
Preclinical Studies in Osteoarthritis
1999We are entering into a new era as a myriad of new approaches to the treatment of osteoarthritis (OA) is under development. While the traditional therapies have been directed at symptoms, many of the new approaches are directed at structure (disease) modification.
M. Sisay, R. D. Altman
openaire +1 more source

